



TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

**AUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL YEAR ENDED
30 JUNE 2025**

Contact

Level 11, No.11, Jalan Teknologi,
Taman Sains Selangor 1, PJU 5,
Kota Damansara
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111
Fax: +603 6287 1212

www.tmclife.com

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

AUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2025

	Individual Quarter		12 months ended	
	Current Year Quarter	Preceding Year Quarter	Current Year To Date	Preceding Year Corresponding Period
	30/06/2025 RM'000	30/06/2024 RM'000	30/06/2025 RM'000	30/06/2024 RM'000
Revenue	93,273	74,124	345,538	346,418
Other operating income	1,407	834	4,601	4,164
Inventories and consumables	(34,991)	(24,413)	(118,019)	(101,314)
Staff costs	(29,230)	(27,332)	(117,946)	(107,089)
Other operating expenses	(16,683)	(14,187)	(67,832)	(56,865)
Depreciation and amortisation	(9,195)	(7,549)	(34,101)	(27,905)
Interest income	706	1,397	4,167	5,466
Finance costs	(2,233)	(2,533)	(9,336)	(10,254)
Profit before taxation	3,054	341	7,072	52,621
Taxation	(631)	683	(3,466)	(11,973)
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	2,423	1,024	3,606	40,648
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year attributable to:-				
Owners of the parent	2,423	1,024	3,606	40,648
Profit per ordinary share attributable to the owners of the parent (sen)				
Basic/diluted	0.14	0.06	0.21	2.33

The audited condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

AUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2025

	Attributable to owners of the parent			Total equity RM'000
	Share capital RM'000	Non-distributable	Distributable	
		Share options reserve RM'000	Retained profits RM'000	
Balance at 1 July 2024	625,986	1,316	260,732	888,034
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	-	-	3,606	3,606
Transactions with owners				
Share options granted under ESOS	-	19	-	19
Transfer within reserve for ESOS forfeited	-	(1,335)	1,335	-
Dividend paid	-	-	(38,616)	(38,616)
Total transactions with owners	-	(1,316)	(37,281)	(38,597)
Balance at 30 June 2025	625,986	-	227,057	853,043
Balance at 1 July 2023	625,986	1,415	234,558	861,959
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	-	-	40,648	40,648
Transactions with owners				
Share options granted under ESOS	-	55	-	55
Transfer within reserve for ESOS forfeited	-	(154)	154	-
Dividend paid	-	-	(14,628)	(14,628)
Total transactions with owners	-	(99)	(14,474)	(14,573)
Balance at 30 June 2024	625,986	1,316	260,732	888,034

The audited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the interim financial statements.

AUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2025

	As At 30/06/2025 Audited RM'000	As At 30/06/2024 Audited RM'000
Non-current assets		
Property, plant and equipment	725,778	718,274
Intangible assets	201,192	206,494
Investment property	2,039	2,099
Deferred tax assets	700	315
Total non-current assets	929,709	927,182
Current assets		
Inventories	15,908	11,622
Trade and other receivables	65,600	51,592
Tax recoverable	11,409	10,755
Cash and bank balances	109,564	188,572
Total current assets	202,481	262,541
TOTAL ASSETS	1,132,190	1,189,723
Current liabilities		
Contract liabilities	519	525
Trade and other payables	69,286	72,035
Borrowings	38,047	23,488
Lease liabilities	1,901	1,814
Provision	-	381
Income tax payable	559	377
Total current liabilities	110,312	98,620
NET CURRENT ASSETS	92,169	163,921
Non-current liabilities		
Contract liabilities	357	257
Borrowings	141,426	179,270
Lease liabilities	1,598	662
Provision	739	222
Deferred tax liabilities	24,715	22,658
Total non-current liabilities	168,835	203,069
TOTAL LIABILITIES	279,147	301,689
NET ASSETS	853,043	888,034
Represented by:		
Equity attributable to owners of the parent		
Share capital	625,986	625,986
Reserves	-	1,316
Retained profits	227,057	260,732
TOTAL EQUITY	853,043	888,034
Net assets per share (RM)	0.49	0.51

The audited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the interim financial statements.

AUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2025

	Current Year To Date 30/06/2025 RM'000	Preceding Year Corresponding Period 30/06/2024 RM'000
Cash flows from operating activities		
Profit before tax	7,072	52,621
Adjustments for :-		
Non-cash items	34,931	28,264
Interest expense	9,336	10,254
Interest income	(4,167)	(5,466)
Operating profit before changes in working capital	47,172	85,673
Changes in working capital		
Net change in current assets	(19,083)	10,365
Net change in trade and other payables and contract liabilities	5,809	(10,124)
Cash generated from operations	33,898	85,914
Interest paid	(9,126)	(10,176)
Net income tax paid	(2,266)	(975)
Net cash flows generated from operating activities	22,506	74,763
Cash flows used in investing activities		
Acquisition of property, plant and equipment	(40,707)	(25,350)
Acquisition of intangible assets	(432)	(3,195)
Proceeds from disposal of property, plant and equipment	12	-
Withdrawal/(Placement) of deposits placed with:-		
- financial institutions with original maturity of more than three (3) months	32,225	(31,058)
- deposits pledged	94	(36)
Interest received	4,167	5,466
Net cash flows generated used in investing activities	(4,641)	(54,173)
Cash flows used in financing activities		
Dividend paid	(38,616)	(14,628)
Payment of lease liabilities	(2,461)	(2,027)
Drawdown of term loans	-	2,978
Repayment of term loans	(22,595)	(15,097)
Repayment of hire purchase	(882)	(882)
Net cash flows used in financing activities	(64,554)	(29,656)
Net decrease in cash & cash equivalents	(46,689)	(9,066)
Cash & cash equivalents at beginning of the financial year	107,511	116,577
Cash & cash equivalents at end of the financial year	60,822	107,511
Cash & cash equivalents at end of the financial year		
Cash at banks and on hand	43,555	60,003
Deposits with licenced banks	66,009	128,569
	109,564	188,572
Less: Deposits with licensed banks (for more than 3 months)	(44,636)	(76,861)
Deposit pledged to a licenced bank	(1,646)	(1,740)
Cash restricted in use	(2,460)	(2,460)
	60,822	107,511

The audited condensed consolidated statement of cash flows should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

**NOTES TO THE AUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2025**

**A EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING
STANDARDS ("MFRS")**

A1 BASIS OF PREPARATION

The interim financial report is audited and has been prepared in compliance with Malaysian Financial Reporting Standards ("MFRS") 134 - Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of TMC Life Sciences Berhad and its subsidiaries ("the Group") for the financial year ended 30 June 2024. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant for understanding the changes in the financial position of the Group since the financial year ended 30 June 2024, and changes in financial performance since the preceeding year corresponding period.

The accounting policies and methods of computations used in the preparation of the financial statements are consistent with those adopted in the audited financial statements for the financial year ended 30 June 2024, except for the adoption of the new, revised and amendments to MFRS and IC Interpretations effective as of 1 January 2024 as issued by the Malaysian Accounting Standards Board, which does not have any significant impact on the financial statements of the Group.

A2 SEASONALITY OR CYCLICALITY OF OPERATIONS

The Group's business is typically impacted during festive and holiday periods when a decrease in patient load is anticipated.

A3 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no material items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A4 CHANGE IN ACCOUNTING ESTIMATES

During the financial year, the Group and the Company conducted a review to reassess the useful lives of their intangible assets. This reassessment was conducted in light of the change in plan with regards to the usage of the hospital information management system, resulting in the need to revise the expected useful lives of certain intangible assets.

As a result of this review, the useful lives of certain intangibles were revised to better reflect the remaining expected useful lives of certain intangibles, which were previously assessed to have useful lives at annual rates of 10% to 33%, were revised to 25% to 50% with the following impact on the amortisation expense in statement of comprehensive income.

	2025	2026	2027	After 2027
	RM'000	RM'000	RM'000	RM'000
Net increase/(Decrease)				
in amortisation expense	2,967	3,955	(1,762)	(5,160)

The change in estimated useful lives is accounted for prospectively in accordance with MFRS 108 "Accounting Policies, Changes in Accounting Estimates and Errors".

The amortisation expense on computer software with finite life is recognised in the statement of comprehensive income.

A5 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial quarter under review.

A6 DIVIDEND PAID

During the financial year ended 30 June 2025, the Company paid a final single tier dividend of 0.4898 sen and a special single tier dividend of 1.7271 sen per ordinary share on 1,741,882,393 ordinary shares, amounting to RM38,615,761 in respect of the financial year ended 30 June 2024.

A7 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital and fertility centres.

A8 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There was no material event subsequent to 30 June 2025 and up to the date of this report that would likely affect substantially the results of the operations of the Group.

A9 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current quarter under review.

A10 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

Financial guarantees

	30/06/2025	30/06/2024
	RM'000	RM'000
<u>Unsecured</u>		
Corporate guarantees given to licensed bank for banking facility granted to wholly-owned subsidiaries	179,473	202,758
Letter of guarantee given to suppliers	9,225	5,237
	<u>188,698</u>	<u>207,995</u>

A11 CAPITAL COMMITMENTS

The amount of commitments for capital expenditure as at 30 June 2025 is as follows:

	30/06/2025	30/06/2024
	RM'000	RM'000
Approved and contracted for	<u>29,581</u>	<u>49,325</u>

A12 SIGNIFICANT RELATED PARTY TRANSACTIONS

There were no significant related party transactions during the quarter under review.

**NOTES TO THE AUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL YEAR ENDED 30 JUNE 2025**

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)

B1 REVIEW OF THE PERFORMANCE OF THE GROUP

Analysis of performance

Review of results for the financial quarter (3 months ended 30 June 2025 versus 3 months ended 30 June 2024)

	3 months ended	
	30/06/2025	30/06/2024
	RM'000	RM'000
Revenue	93,273	74,124
Profit before taxation	3,054	341

For the quarter ended 30 June 2025, the Group recorded revenue of RM93.3 million and profit before taxation of RM3.1 million, representing an increase of 26% and 796% respectively, compared to the previous corresponding quarter. The increase in profit before taxation was due to higher contribution from our Oncology Centre and reduced discount to corporate customers at Thomson Hospital Kota Damansara ("THKD").

Review of results for the financial year (12 months ended 30 June 2025 versus 12 months ended 30 June 2024)

	12 months ended	
	30/06/2025	30/06/2024
	RM'000	RM'000
Revenue	345,538	346,418
Profit before taxation	7,072	52,621

For the financial year ended 30 June 2025, the Group registered a marginal decline in revenue of 0.3%, amounting to RM345.5 million, compared to the corresponding period in the previous financial year. Profit before taxation decreased significantly by 87% to RM7.1 million, primarily impacted by customer contract discounts, higher operating expenses and depreciation charges. The quarter ended 30 June 2025 rebounded, demonstrating improved fundamentals, providing a strong momentum into the new financial year.

Material factors affecting the earnings and / or revenue of the Group

The material factors that affect the earnings and / or revenue of the Group are the successful recruitment of healthcare professionals in our facilities, additional bed capacity and additional services offered by the Group, higher case intensity handled, and continuous marketing effort to boost local and international branding.

**B2 MATERIAL CHANGE IN PROFIT BEFORE TAX AS COMPARED WITH IMMEDIATE PRECEDING QUARTER
(3 months ended 30 June 2025 versus 3 months ended 31 March 2025)**

	3 months ended	
	30/06/2025	31/03/2025
	RM'000	RM'000
Revenue	93,273	89,872
Profit before taxation	3,054	52

Compared to the immediate preceding quarter ended 31 March 2025, revenue increased by 4% and profit before taxation recorded significant improvement. The growth was driven by higher contribution from our Oncology Centre as well as prudent cost management.

B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 30 JUNE 2026

Global economic uncertainties arising from rising tariffs and trade restrictions continue to impact various industries. These challenges may result in higher costs of medical supplies and some supply chain disruptions. The Group is actively monitoring developments and will continue to implement mitigating measures to ensure operational resilience and business sustainability.

Despite the external headwinds, the Group remains optimistic about future growth prospects. Growth is expected to be supported by the increased capacity at THKD and the ongoing expansion of the Oncology Centre. The Group is also pursuing medical tourism and onboarding new corporate customers to diversify its revenue base.

The Group will continue to implement strategic initiatives focused on enhancing operational efficiency and expanding its customer base. Management remains committed to driving sustainable growth and improving profitability through cost optimisation and exploration of new services.

B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

There is no profit forecast or profit guarantee for the financial period ended 30 June 2025.

B5 TAXATION

	Individual quarter		12 months ended	
	30/06/2025	30/06/2024	30/06/2025	30/06/2024
	RM'000	RM'000	RM'000	RM'000
In respect of current quarter / financial year				
Current tax expense/(credit)	264	(101)	1,794	1,947
Deferred tax expense/(credit)	367	(582)	1,672	10,026
	<u>631</u>	<u>(683)</u>	<u>3,466</u>	<u>11,973</u>

Tax provision during the current quarter refers to recognition of tax expense for profit making subsidiaries.

B6 STATUS OF CORPORATE PROPOSAL

There are no corporate proposals announced but not completed as at 19 August 2025, being the latest practicable date which shall not be earlier than 7 days from the date of this quarterly report.

B7 BORROWINGS

The Group's borrowings are as follows:-

	Long Term	Short Term	Total
	RM'000	RM'000	RM'000
As at 30 June 2025			
Secured - Denominated in Ringgit Malaysia	<u>141,426</u>	<u>38,047</u>	<u>179,473</u>
As at 30 June 2024			
Secured - Denominated in Ringgit Malaysia	<u>179,270</u>	<u>23,488</u>	<u>202,758</u>

Included in borrowings of the Group is an amount of Industrial Hire Purchase of RM442,000 (30 June 2024: RM1,328,000).

B8 MATERIAL LITIGATION

There was no material litigation as at the date of this report.

B9 DIVIDENDS

Subject to the approval of the shareholders at the forthcoming Annual General Meeting, the Board recommends a first and final single-tier dividend of 0.1863 sen per ordinary share for the financial year ended 30 June 2025 (30 June 2024 - first and final single-tier dividend of 0.4898 sen per ordinary share and a special single-tier dividend of 1.7271 sen per ordinary share). The net amount payable is RM3.25 million (30 June 2024 : RM38.6 million).

B10 EARNINGS PER SHARE (EPS)

	Individual quarter		12 months ended	
	30/06/2025	30/06/2024	30/06/2025	30/06/2024
(a) Basic EPS				
Net profit attributable to owners of the parent (RM'000)	2,423	1,024	3,606	40,648
Weighted average number of ordinary shares in issue ('000)	1,741,882	1,741,882	1,741,882	1,741,882
EPS (sen)				
- Basic	0.14	0.06	0.21	2.33
(b) Diluted EPS				

There was no dilution in the earnings per share of the Group in the previous financial year as the share price of the Company as at the reporting date was lower than the exercise prices. The effect of assumed conversion of ESOS outstanding will be anti-dilutive and as such, the diluted earnings per share is the same as the basic earnings per share.

During the current financial year, all unexercised ESOS options lapsed on 28 May 2025. Consequently, there was no dilution in the earnings per share of the Group as at the reporting date.

B11 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The audit report of the preceding annual financial statements was unqualified.

B12 NOTE TO STATEMENT OF COMPREHENSIVE INCOME

	Individual quarter		12 months ended	
	30/06/2025	30/06/2024	30/06/2025	30/06/2024
	RM'000	RM'000	RM'000	RM'000
Interest income	706	1,397	4,167	5,466
Interest expense	(2,230)	(2,527)	(9,322)	(10,246)
Unwinding of discount on provision for restoration	(3)	(6)	(14)	(8)
Depreciation of property, plant and equipment, investment property and right-of-use assets	(7,507)	(6,355)	(28,249)	(25,155)
Amortisation of intangible assets	(1,688)	(1,194)	(5,852)	(2,750)
Impairment loss on receivables	(16)	-	(646)	(147)
Fair value charges on share options granted under ESOS	(4)	(15)	(19)	(55)
Property, plant and equipment written off	(23)	(29)	(36)	(68)
Gain on disposal of property, plant and equipment	10	-	12	-
Gain on derecognition of lease liability	1	1	2	42
Inventories written off	(21)	(24)	(143)	(131)
Reversal of impairment loss on receivables	-	483	-	-

B13 DERIVATIVE FINANCIAL INSTRUMENTS

The Group did not enter into any derivative financial instruments which were outstanding as at 30 June 2025 and 30 June 2024.

B14 AUTHORISED FOR ISSUE

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 26 August 2025.